Administrative and Coordination Core

行政及协调核心

基本信息

  • 批准号:
    10708105
  • 负责人:
  • 金额:
    $ 60.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-30 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY ADMINISTRATIVE (ADMIN) CORE The Administration (ADMIN) Core of the Indiana University (IU)/Jackson Laboratory (JAX)/University of Pittsburgh (PITT) Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease Center (IU/JAX/PITT MODEL-AD), led by ADMIN Head Dr. Bruce Lamb at IU with assistance from multiple Principle Investigators (mPIs) Drs. Paul Territo and Adrian Oblak at IU, Drs. Greg Carter, Gareth Howell, and Mike Sasner at JAX, Dr. Stacey Rizzo at PITT, and Dr. Anna Greenwood at Sage Bionetworks and with the support of Program Co-Managers and full-time administrators at both IU and JAX, will oversee all administrative and scientific functions of the Center. The ADMIN Core will execute these duties with oversight from an External Advisory Board (EAB) comprising leading experts in the field and a Center Steering Committee (CSC) comprising IU/JAX/PITT and UCI MODEL-AD Center PIs and NIH program officials. The EAB will convene annually, the CSC monthly, and the entire MODEL-AD consortium monthly to review progress and provide input and feedback (oral and written) to ensure that the Center (1) achieves its mission, aims, milestones, and metrics; (2) coordinates efforts across the two MODEL-AD Centers; (3) effectively deals with any unanticipated problems or concerns; and (4) adapts to likely experimental and technical advances in the field. There will be biweekly ADMIN, BDMC, DMP, and PTC meetings and joint BDMC/DMP meetings. These will be focused on issues unique to specific Cores/Projects while ensuring maximal synergy among the various components of the IU/JAX/PITT MODEL-AD Center. Close interaction will be fostered among the BDMC, PTC, and the DMP, thus facilitating timely discoveries while reducing overall costs. One of the primary goals of the ADMIN Core will be to ensure that discoveries made in one area of the Center will benefit the Center overall, leading to efficiencies in time and cost. Finally, the ADMIN Core will also promote Center interactions and meetings with other ongoing research efforts in the Alzheimer’s research community, including the NIA-supported ADRCs, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the Alzheimer’s Disease Accelerating Medicine’s Partnership (AMP-AD), and the Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) consortium. The Specific Aims of the IU/JAX/PITT MODEL-AD ADMIN Core are as follows: 1. Provide effective and efficient management, oversight, and evaluation of the IU/JAX/PITT MODEL-AD Center and its interactions with the AD research community. 2. Ensure timely and successful completion of all Project and Core aims and milestones. 3. Facilitate interactions between and among the Bioinformatics and Data Management Core, the Preclinical Testing Core, and the Disease Model Project.
项目摘要管理(管理)核心 印第安纳州大学(IU)/杰克逊实验室(JAX)/印第安纳大学管理中心(ADMIN) 匹兹堡(PITT)晚发性阿尔茨海默病中心模型生物体开发和评价 (IU/JAX/PITT MODEL-AD),由IU的管理负责人布鲁斯兰姆博士领导,并得到多个 主要研究者(mPI)IU的Paul Terito博士和Adrian Oblak博士,Greg Carter博士,Gareth豪厄尔博士, JAX的Mike Sasner、PITT的Stacey Rizzo博士和Sage Bionetworks的安娜格林伍德博士, 在IU和JAX的项目联合经理和全职管理员的支持下, 中心的行政和科学职能。ADMIN核心将执行这些职责, 外部咨询委员会(EAB)的监督,该委员会由该领域的领先专家和中心组成 指导委员会(CSC),包括IU/JAX/PITT和UCI MODEL-AD中心PI和NIH计划 官员EAB每年召开一次会议,CSC每月召开一次会议,整个MODEL AD联盟每月召开一次会议 审查进展情况,并提供输入和反馈(口头和书面),以确保中心(1)实现 其使命、目标、里程碑和指标;(2)协调两个模型-AD中心的工作;(3) 有效地处理任何意想不到的问题或关注;(4)适应可能的实验和 该领域的技术进步。将每两周举行一次管理员、业务数据管理委员会、信息技术委员会和技术合作委员会会议, 发展监测委员会会议。这些将侧重于特定核心/项目特有的问题,同时确保 IU/JAX/PITT MODEL-AD中心各组成部分之间的最大协同作用。密切互动 将在BDMC、PTC和TQM之间进行培养,从而促进及时发现,同时减少 总成本。ADMIN核心的主要目标之一是确保在一个 该中心的面积将有利于该中心的整体,导致在时间和成本的效率。最后,管理员 核心还将促进中心的互动和会议与其他正在进行的研究工作, 阿尔茨海默氏症研究社区,包括NIA支持的ADRC,阿尔茨海默氏症 神经影像学倡议(ADNI),阿尔茨海默病加速医学伙伴关系(AMP-AD), 以及加速阿尔茨海默病(AD)治疗开发的目标实现 财团 IU/JAX/PITT MODEL-AD ADMIN核心的具体目标如下: 1.对IU/JAX/PITT进行有效和高效的管理、监督和评估 模型AD中心及其与AD研究社区的互动。 2.确保及时和成功地完成所有项目和核心目标和里程碑。 3.促进生物信息学和数据管理核心、 临床前测试核心和疾病模型项目。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bruce T Lamb其他文献

The PI3K-Akt-mTOR pathway regulates Aβ oligomer induced neuronal cell cycle events
  • DOI:
    10.1186/1750-1326-4-14
  • 发表时间:
    2009-03-16
  • 期刊:
  • 影响因子:
    17.500
  • 作者:
    Kiran Bhaskar;Megan Miller;Alexandra Chludzinski;Karl Herrup;Michael Zagorski;Bruce T Lamb
  • 通讯作者:
    Bruce T Lamb
Right sizing funding for Alzheimer's disease
  • DOI:
    10.1186/alzrt76
  • 发表时间:
    2011-01-01
  • 期刊:
  • 影响因子:
    7.600
  • 作者:
    Todd E Golde;Bruce T Lamb;Douglas Galasko
  • 通讯作者:
    Douglas Galasko

Bruce T Lamb的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bruce T Lamb', 18)}}的其他基金

Deciphering the role of CX3CR1 in Modulating Mechanisms of Amyloid driven Neurodegeneration in Alzheimer's Disease (Diversity Supplement)
破译 CX3CR1 在阿尔茨海默氏病淀粉样蛋白驱动的神经变性调节机制中的作用(多样性补充)
  • 批准号:
    10524900
  • 财政年份:
    2020
  • 资助金额:
    $ 60.48万
  • 项目类别:
IUSM Alzheimer's Disease Drug Discovery Center
IUSM 阿尔茨海默病药物研发中心
  • 批准号:
    10250434
  • 财政年份:
    2019
  • 资助金额:
    $ 60.48万
  • 项目类别:
IUSM Alzheimer's Disease Drug Discovery Center
IUSM 阿尔茨海默病药物研发中心
  • 批准号:
    10684136
  • 财政年份:
    2019
  • 资助金额:
    $ 60.48万
  • 项目类别:
IUSM Alzheimer's Disease Drug Discovery Center
IUSM 阿尔茨海默病药物研发中心
  • 批准号:
    10017136
  • 财政年份:
    2019
  • 资助金额:
    $ 60.48万
  • 项目类别:
IUSM Alzheimer's Disease Drug Discovery Center
IUSM 阿尔茨海默病药物研发中心
  • 批准号:
    10851513
  • 财政年份:
    2019
  • 资助金额:
    $ 60.48万
  • 项目类别:
Enzymatic substrates for HTS: IUSM Alzheimer's Disease Drug Discovery Center
HTS 的酶底物:IUSM 阿尔茨海默病药物发现中心
  • 批准号:
    10171202
  • 财政年份:
    2019
  • 资助金额:
    $ 60.48万
  • 项目类别:
IUSM Alzheimer's Disease Drug Discovery Center: PTC Software
IUSM 阿尔茨海默病药物研发中心:PTC 软件
  • 批准号:
    10198429
  • 财政年份:
    2019
  • 资助金额:
    $ 60.48万
  • 项目类别:
IU/JAX/Pitt MODEL-AD: MAPT-GR
IU/JAX/皮特 模型-AD:MAPT-GR
  • 批准号:
    10198518
  • 财政年份:
    2016
  • 资助金额:
    $ 60.48万
  • 项目类别:
Administrative and Coordination Core
行政及协调核心
  • 批准号:
    10402548
  • 财政年份:
    2016
  • 资助金额:
    $ 60.48万
  • 项目类别:
Administrative and Coordination Core
行政及协调核心
  • 批准号:
    10590446
  • 财政年份:
    2016
  • 资助金额:
    $ 60.48万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 60.48万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 60.48万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 60.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 60.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 60.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 60.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 60.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 60.48万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 60.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 60.48万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了